BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
Number Cited Articles
1
ATP-binding cassette transporter ABCG2 (BCRP) and ABCB1 (MDR1) variants are not associated with disease susceptibility, disease phenotype response to medical therapy or need for surgeryin Hungarian patients with inflammatory bowel diseasesScandinavian Journal of Gastroenterology 2007; 42(6): 726 doi: 10.1080/00365520601101559
2
Lilla Lakner, Veronika Csöngei, Patrícia Sarlós, Luca Járomi, Enikő Sáfrány, Márta Varga, Péter Orosz, Lili Magyari, Judit Bene, Pál Miheller, Zsolt Tulassay, Béla Melegh. IGR2096a_1 T and IGR2198a_1 C alleles on IBD5 locus of chromosome 5q31 region confer risk for Crohn’s disease in Hungarian patientsInternational Journal of Colorectal Disease 2009; 24(5): 503 doi: 10.1007/s00384-009-0670-x
3
Jonathan L. Digby-Bell, Raja Atreya, Giovanni Monteleone, Nick Powell. Interrogating host immunity to predict treatment response in inflammatory bowel diseaseNature Reviews Gastroenterology & Hepatology 2020; 17(1): 9 doi: 10.1038/s41575-019-0228-5
4
Wouter M. Kooloos, Dirk J. de Jong, Tom W.J. Huizinga, Henk-Jan Guchelaar. Potential role of pharmacogenetics in anti-TNF treatment of rheumatoid arthritis and Crohn's diseaseDrug Discovery Today 2007; 12(3-4): 125 doi: 10.1016/j.drudis.2006.11.013
5
Corey A. Siegel, Gil Y. Melmed. Review: Predicting response to anti-TNF agents for the treatment of Crohn's diseaseTherapeutic Advances in Gastroenterology 2009; 2(4): 245 doi: 10.1177/1756283X09336364
6
Ashwin N. Ananthakrishnan, Ramnik J. Xavier. How Does Genotype Influence Disease Phenotype in Inflammatory Bowel Disease?Inflammatory Bowel Diseases 2013; : 1 doi: 10.1097/MIB.0b013e318281f5c5
7
Ulrich Klotz, Alexander Teml, Matthias Schwab. Clinical Pharmacokinetics and Use??of??InfliximabClinical Pharmacokinetics 2007; 46(8): 645 doi: 10.2165/00003088-200746080-00002
8
Marla C. Dubinsky, Ling Mei, Madison Friedman, Tanvi Dhere, Talin Haritunians, Hakon Hakonarson, Cecilia Kim, Joseph Glessner, Stephan R. Targan, Dermot P. McGovern, Kent D. Taylor, Jerome I. Rotter. Genome wide association (GWA) predictors of anti-TNFα therapeutic responsiveness in pediatric inflammatory bowel diseaseInflammatory Bowel Diseases 2010; 16(8): 1357 doi: 10.1002/ibd.21174
9
Karen van Hoeve, Ilse Hoffman, Severine Vermeire. Therapeutic drug monitoring of anti-TNF therapy in children with inflammatory bowel diseaseExpert Opinion on Drug Safety 2018; 17(2): 185 doi: 10.1080/14740338.2018.1413090
10
Johan Van Limbergen, Richard K. Russell, Elaine R. Nimmo, Jack Satsangi. The Genetics of Inflammatory Bowel DiseaseThe American Journal of Gastroenterology 2007; 102(12): 2820 doi: 10.1111/j.1572-0241.2007.01527.x
11
Mahmoud H Mosli, William J Sandborn, Richard B Kim, Reena Khanna, Bandar Al-Judaibi, Brian G Feagan. Toward a Personalized Medicine Approach to the Management of Inflammatory Bowel DiseaseAmerican Journal of Gastroenterology 2014; 109(7): 994 doi: 10.1038/ajg.2014.110
12
Vinciane Dideberg, Emilie Théâtre, Frédéric Farnir, Séverine Vermeire, Paul Rutgeerts, Martine De Vos, Jacques Belaiche, Denis Franchimont, André Van Gossum, Edouard Louis, Vincent Bours. The TNF/ADAM 17 system: implication of an ADAM 17 haplotype in the clinical response to infliximab in Crohnʼs diseasePharmacogenetics and Genomics 2006; 16(10): 727 doi: 10.1097/01.fpc.0000230117.26581.a4
13
Ad A. van Bodegraven, Cisca Wijmenga. Essentials of Genomic and Personalized Medicine2010; : 575 doi: 10.1016/B978-0-12-374934-5.00045-3
14
Vinciane Dideberg, E. Louis, V. Bours. Pharmacogénétique de l’infliximab dans la maladie de CrohnActa Endoscopica 2007; 37(4): 521 doi: 10.1007/BF02961799
15
Jimmy K Limdi, Katherine A Siminovitch, William Newman. Genetic dissection of inflammatory bowel disease: unravelling etiology and improving diagnosticsExpert Review of Clinical Immunology 2005; 1(4): 609 doi: 10.1586/1744666X.1.4.609
16
Melissa A Smith, Anthony M Marinaki, Jeremy D Sanderson. Pharmacogenomics in the treatment of inflammatory bowel diseasePharmacogenomics 2010; 11(3): 421 doi: 10.2217/pgs.10.4
17
B. Weiss, O. Lebowitz, H. H. Fidder, I. Maza, A. Levine, R. Shaoul, S. Reif, Y. Bujanover, A. Karban. Response to Medical Treatment in Patients with Crohn’s Disease: The Role of NOD2/CRAD15, Disease Phenotype, and Age of DiagnosisDigestive Diseases and Sciences 2010; 55(6): 1674 doi: 10.1007/s10620-009-0936-8
18
Loris Lopetuso, Viviana Gerardi, Valerio Papa, Franco Scaldaferri, Gian Rapaccini, Antonio Gasbarrini, Alfredo Papa. Can We Predict the Efficacy of Anti-TNF-α Agents?International Journal of Molecular Sciences 2017; 18(9): 1973 doi: 10.3390/ijms18091973
19
Kristin E Burke, Hamed Khalili, John J Garber, Talin Haritunians, Dermot P B McGovern, Ramnik J Xavier, Ashwin N Ananthakrishnan. Genetic Markers Predict Primary Nonresponse and Durable Response to Anti–Tumor Necrosis Factor Therapy in Ulcerative ColitisInflammatory Bowel Diseases 2018; 24(8): 1840 doi: 10.1093/ibd/izy083
20
Michael Camilleri. The role of pharmacogenetics in nonmalignant gastrointestinal diseasesNature Reviews Gastroenterology & Hepatology 2012; 9(3): 173 doi: 10.1038/nrgastro.2012.2
21
Ad A. van Bodegraven, Cisca Wijmenga. Genomic and Personalized Medicine2009; : 1040 doi: 10.1016/B978-0-12-369420-1.00086-X
22
Boris Gole, Uroš Potočnik. Pre-Treatment Biomarkers of Anti-Tumour Necrosis Factor Therapy Response in Crohn’s Disease—A Systematic Review and Gene Ontology AnalysisCells 2019; 8(6): 515 doi: 10.3390/cells8060515
23
Eleanora Anna Margaretha Festen, Cisca Wijmenga, Rinse K Weersma. Genomic and Personalized Medicine2013; : 863 doi: 10.1016/B978-0-12-382227-7.00073-2
24
Uri Netz, Jane Victoria Carter, Maurice Robert Eichenberger, Gerald Wayne Dryden, Jianmin Pan, Shesh Nath Rai, Susan Galandiuk. Genetic polymorphisms predict response to anti-tumor necrosis factor treatment in Crohn’s diseaseWorld Journal of Gastroenterology 2017; 23(27): 4958-4967 doi: 10.3748/wjg.v23.i27.4958
25
Javier P Gisbert, María Chaparro. Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical PracticeJournal of Crohn's and Colitis 2019;  doi: 10.1093/ecco-jcc/jjz195
26
Alexander Teml, Susanne Karner, Elke Schaeffeler, Matthias Schwab. Pharmacogenetics and Individualized Therapy2012; : 323 doi: 10.1002/9781118116494.ch11
27
Ryan Ungaro, Judy Cho. Biomarkers in Inflammatory Bowel Diseases2019; : 333 doi: 10.1007/978-3-030-11446-6_28
28
Konstantinos Papamichael, Ann Gils, Paul Rutgeerts, Barrett G. Levesque, Séverine Vermeire, William J. Sandborn, Niels Vande Casteele. Role for Therapeutic Drug Monitoring During Induction Therapy with TNF Antagonists in IBDInflammatory Bowel Diseases 2015; 21(1): 182 doi: 10.1097/MIB.0000000000000202
29
Philippe Goyette, Catherine Labbé, Truc T. Trinh, Ramnik J. Xavier, John D. Rioux. Molecular pathogenesis of inflammatory bowel disease: Genotypes, phenotypes and personalized medicineAnnals of Medicine 2007; 39(3): 177 doi: 10.1080/07853890701197615
30
Grant E Barber, Vijay Yajnik, Hamed Khalili, Cosmas Giallourakis, John Garber, Ramnik Xavier, Ashwin N Ananthakrishnan. Genetic Markers Predict Primary Non-Response and Durable Response To Anti-TNF Biologic Therapies in Crohn’s DiseaseAmerican Journal of Gastroenterology 2016; 111(12): 1816 doi: 10.1038/ajg.2016.408
31
Katja Repnik, Uroš Potočnik. Haplotype in the IBD5 region is associated with refractory Crohn’s disease in Slovenian patients and modulates expression of the SLC22A5 geneJournal of Gastroenterology 2011; 46(9): 1081 doi: 10.1007/s00535-011-0426-6
32
Mathurin Flamant, Xavier Roblin. Inflammatory bowel disease: towards a personalized medicineTherapeutic Advances in Gastroenterology 2018; 11: 1756283X1774502 doi: 10.1177/1756283X17745029
33
Vinciane Dideberg, Edouard Louis, Frédéric Farnir, Sabrina Bertoli, Séverine Vermeire, Paul Rutgeerts, Martine De Vos, André Van Gossum, Jacques Belaiche, Vincent Bours. Lymphotoxin alpha gene in Crohnʼs disease patients: absence of implication in the response to infliximab in a large cohort studyPharmacogenetics and Genomics 2006; 16(5): 369 doi: 10.1097/01.fpc.0000204993.91806.b1
34
Leif Törkvist, Colin L. Noble, Mikael Lördal, Urban Sjöqvist, Ulrik Lindforss, Elaine R. Nimmo, Robert Löfberg, Richard K. Russell, Jack Satsangi. Contribution of the IBD5 locus to Crohn's disease in the Swedish populationScandinavian Journal of Gastroenterology 2007; 42(2): 200 doi: 10.1080/00365520600842278
35
Rita Prajapati, Darren Plant, Anne Barton. Genetic and genomic predictors of anti-TNF responsePharmacogenomics 2011; 12(11): 1571 doi: 10.2217/pgs.11.114
36
Alfonso Martínez, Maria del Carmen Martín, Juan L Mendoza, Carlos Taxonera, Manuel Díaz-Rubio, Emilio G de la Concha, Elena Urcelay. Association of the organic cation transporter OCTN genes with Crohn's disease in the Spanish populationEuropean Journal of Human Genetics 2006; 14(2): 222 doi: 10.1038/sj.ejhg.5201529
37
Ashwin N Ananthakrishnan. Personalizing therapy for inflammatory bowel diseasesExpert Review of Gastroenterology & Hepatology 2013; 7(6): 549 doi: 10.1586/17474124.2013.824693
38
N. S. Ding, A. Hart, P. De Cruz. Systematic review: predicting and optimising response to anti-TNF therapy in Crohn's disease - algorithm for practical managementAlimentary Pharmacology & Therapeutics 2016; 43(1): 30 doi: 10.1111/apt.13445
39
K. R. HERRLINGER, D. P. JEWELL. Review article: interactions between genotype and response to therapy in inflammatory bowel diseasesAlimentary Pharmacology and Therapeutics 2006; 24(10): 1403 doi: 10.1111/j.1365-2036.2006.03147.x
40
Michael J. Murphy, Carlo Pincelli, Diane M. Hoss, Riccardo G. Borroni. Molecular Diagnostics in Dermatology and Dermatopathology2011; : 419 doi: 10.1007/978-1-60761-171-4_21
41
Cecile Krejsa, Mark Rogge, Wolfgang Sadee. Protein therapeutics: new applications for pharmacogeneticsNature Reviews Drug Discovery 2006; 5(6): 507 doi: 10.1038/nrd2039
42
Seiya Nakahara, Yoshiaki Arimura, Katsuhiko Saito, Akira Goto, Satoshi Motoya, Yasuhisa Shinomura, Atsushi Miyamoto, Kohzoh Imai. Association of SLC22A4/5 Polymorphisms with Steroid Responsiveness of Inflammatory Bowel Disease in JapanDiseases of the Colon & Rectum 2008; 51(5): 598 doi: 10.1007/s10350-008-9208-5
43
Lili Magyari, Judit Bene, Katalin Komlósi, Gábor Talián, Bernadett Faragó, Veronika Csöngei, Luca Járomi, Enikő Sáfrány, Csilla Sipeky, Lilla Lakner, Márta Varga, Beáta Gasztonyi, Béla Melegh. Prevalence of SLC22A4 1672T and SLC22A5 −207C combination defined TC haplotype in Hungarian ulcerative colitis patientsPathology & Oncology Research 2007; 13(1): 53 doi: 10.1007/BF02893441
44
Jason Reinglas, Lorant Gonczi, Zsuzsanna Kurt, Talat Bessissow, Peter L Lakatos. Positioning of old and new biologicals and small molecules in the treatment of inflammatory bowel diseasesWorld Journal of Gastroenterology 2018; 24(32): 3567-3582 doi: 10.3748/wjg.v24.i32.3567
45
Michael Economou, Georgios Pappas. New global map of Crohnʼs disease: Genetic, environmental, and socioeconomic correlationsInflammatory Bowel Diseases 2008; 14(5): 709 doi: 10.1002/ibd.20352
46
Carlo Pincelli, Marco Pignatti, Riccardo G. Borroni. Pharmacogenomics in dermatology: from susceptibility genes to personalized therapyExperimental Dermatology 2009; 18(4): 337 doi: 10.1111/j.1600-0625.2009.00852.x
47
Uri Kopylov, Ernest Seidman. Predicting durable response or resistance to antitumor necrosis factor therapy in inflammatory bowel diseaseTherapeutic Advances in Gastroenterology 2016; 9(4): 513 doi: 10.1177/1756283X16638833
48
Claudia Reinhard, John D. Rioux. Role of the IBD5 susceptibility locus in the inflammatory bowel diseasesInflammatory Bowel Diseases 2006; 12(3): 227 doi: 10.1097/01.MIB.0000202413.16360.a1
49
Anna Latiano, O. Palmieri, Rossella M. Valvano, Renata D'Inca, Maurizio Vecchi, Angelo Ferraris, Giacomo C. Sturniolo, Luisa Spina, Giovanni Lombardi, Bruno Dallapiccola, Angelo Andriulli, Marcella Devoto, Vito Annese. Contribution of IBD5 Locus to Clinical Features of IBD PatientsThe American Journal of Gastroenterology 2006; 101(2): 318 doi: 10.1111/j.1572-0241.2006.00389.x
50
Rebecca L Roberts, Murray L Barclay. Current relevance of pharmacogenetics in immunomodulation treatment for Crohn's diseaseJournal of Gastroenterology and Hepatology 2012; 27(10): 1546 doi: 10.1111/j.1440-1746.2012.07220.x
51
Johan Van Limbergen, Richard K. Russell, Elaine R. Nimmo, Gwo-Tzer Ho, Ian D. Arnott, David C. Wilson, Jack Satsangi. Genetics of the innate immune response in inflammatory bowel diseaseInflammatory Bowel Diseases 2007; 13(3): 338 doi: 10.1002/ibd.20096
52
Gonzalo Jesús Gómez-Gómez, Ángeles Masedo, Carmen Yela, Maria del Pilar Martínez-Montiel, Begoña Casís. Current stage in inflammatory bowel disease: What is next?World Journal of Gastroenterology 2015; 21(40): 11282-11303 doi: 10.3748/wjg.v21.i40.11282